January 2024

MARKHAM, ON, Jan. 30, 2024 /CNW/ – Today, Astellas Pharma Canada, Inc. announced that Health Canada has approved a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting. With this approval, XTANDI becomes the first and only androgen receptor

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: